CD8A and neoplasm: Combination led to induction of type 1 interferon and activation of T and B lymphocytes, NK and NKT cells. Combination treatment primed an anti-tumour CD8+ T cell response. Long-term surviving mice had significantly greater frequency of tumour antigen-specific CD8+ T cells.